The market may have finally Weeble wobbled a bit at all-time highs yesterday. Sellers came in and beat up some of the highest performing names of the last couple of week, although they spared quantum names. It sets us up to buy the dip this morning, but you have to be careful. Not every stock out there that dips is buy worthy. Lean on the power of the Zacks Rank to figure out which ones are. All you need to find Is a Zacks Rank #1 (Strong Buy) that’s seeing its earnings move in the right direction.Today’s B ...

Almonty Industries Inc. (ALM) shares rallied 12.3% in the last trading session to close at $5.95. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 23.5% gain over the past four weeks.Almonty Industries shares have gained following its announcement that it has commenced a large-scale drilling program at its Sangdong Molybdenum Project in Yeongwol, Gangwon Province, South Korea. A total of 26 drill holes, spanni ...

Launched on October 25, 2022, the First Trust Indxx Aerospace & Defense ETF (MISL) is a passively managed exchange traded fund designed to provide a broad exposure to the Industrials - Aerospace & Defense segment of the equity market.An increasingly popular option among retail and institutional investors, passively managed ETFs offer low costs, transparency, flexibility, and tax efficiency; they are also excellent vehicles for long term investors.Sector ETFs also provide investors access to a broad group of ...

BigBear.ai Holdings, Inc. (BBAI) shares soared 12.9% in the last trading session to close at $7.99. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 33.6% gain over the past four weeks.BigBear.ai shares likely jumped on key catalysts, including the VeriScan biometric launch at Nashville Airport, a U.S. Navy contract win and renewed AI stock enthusiasm fueled by rate-cut optimism.This company is expected to post quarterly loss of $ ...

Karyopharm Therapeutics (KPTI) shares rallied 27.9% in the last trading session to close at $7.48. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 7.3% loss over the past four weeks.The sudden gain in the stock price can be attributed to a positive investor mindset regarding the continued strong uptake of Karyopharm Therapeutics’ only marketed product, Xpovio (selinexor), approved for multiple myeloma and B-c ...

Alvotech (ALVO) shares rallied 8.6% in the last trading session to close at $8.7. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 3.7% loss over the past four weeks.Alvotech extended its rally for a second day, fueled by optimism after the EMA’s CHMP backed its regulatory filings for biosimilar versions of Amgen’s Prolia/Xgeva and J&J’s Simponi.This company is expected to post quarterly earnings of $0.08 per ...

Core Viewpoint - Pfizer plans to acquire Metsera for $4.9 billion, with potential total value reaching $7.3 billion including milestone payments, aiming to strengthen its position in the obesity drug market projected to be worth $100 billion by 2030 [1][3]. Group 1: Acquisition Details - The acquisition price is set at $47.50 per share, with milestone payments potentially increasing the total to $70 per share [1]. - Metsera's stock surged by 60% to over $50 following the acquisition announcement, while Pfizer's stock remained stable around $24 [2]. - Pfizer will finance the acquisition through cash and debt, while maintaining its dividend and capital priorities [2]. Group 2: Market Context - The obesity drug market is currently dominated by Eli Lilly and Novo Nordisk, with Eli Lilly's Zepbound controlling over 50% of the market and achieving an average weight reduction of 20.2%, compared to Novo Nordisk's Wegovy at 13.5% [4]. - Pfizer previously discontinued its own obesity drug, danuglipron, due to safety concerns [4]. Group 3: Financial Implications - The acquisition could help Pfizer mitigate the impact of upcoming patent expirations for key drugs like Eliquis and Ibrance [5]. - Metsera has raised $316.2 million through its IPO but is not expected to generate significant revenue in the near future [6]. - Pfizer's total sales are projected to slightly increase to $63.81 billion in the current year, with a slight decline expected in FY26 [12]. Group 4: Drug Pipeline - Metsera's MET-097i weight loss drug is in phase two trials, targeting hormones for weight loss and type 2 diabetes treatment [7]. - Metsera's MET-233i drug has shown promising results with an average weight loss of 8.4% in the first five weeks of phase 1 trials [7]. Group 5: Earnings Projections - Pfizer's EPS for FY25 is projected to increase to $3.14, while FY26 EPS is expected to decline to $3.08 [12]. - Metsera's FY25 EPS estimates have improved to a projected loss of -$2.79 per share, but FY26 estimates have worsened to -$3.64 [16].

Core Insights - Micron reported a revenue of $11.32 billion for the quarter ended August 2025, marking a 46% increase year-over-year, with EPS at $3.03 compared to $1.18 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $11.26 billion by 0.47%, and the EPS also surpassed the consensus estimate of $2.86 by 5.94% [1] Revenue Breakdown - DRAM revenue was $8.98 billion, exceeding the average estimate of $8.8 billion, representing a year-over-year increase of 68.7% [4] - Other technology revenue (primarily NOR) was $79 million, above the average estimate of $74.88 million, reflecting a year-over-year growth of 33.9% [4] - NAND revenue was $2.25 billion, slightly below the average estimate of $2.35 billion, showing a year-over-year decline of 4.8% [4] Stock Performance - Micron's shares have returned 41.4% over the past month, significantly outperforming the Zacks S&P 500 composite's 3.6% change [3] - The stock currently holds a Zacks Rank 1 (Strong Buy), indicating potential for outperformance in the near term [3]

Company Performance - Intrusion Inc. closed at $1.89, reflecting a -3.08% change from the previous day, underperforming the S&P 500's loss of 0.55% [1] - Over the past month, shares of Intrusion Inc. gained 8.33%, which is below the Computer and Technology sector's gain of 9.88% but above the S&P 500's gain of 3.64% [1] Upcoming Earnings - Analysts expect Intrusion Inc. to report earnings of -$0.1 per share, indicating a year-over-year growth of 71.43% [2] - The Zacks Consensus Estimate for revenue is projected at $1.91 million, representing a 27.33% increase from the previous year [2] Full Year Estimates - For the full year, analysts anticipate earnings of -$0.38 per share and revenue of $7.74 million, reflecting changes of +76.69% and +34.03% respectively from last year [3] Analyst Estimates - Recent modifications to analyst estimates for Intrusion Inc. indicate shifting business dynamics, with upward revisions suggesting positive sentiment towards the company's operations [4] - The Zacks Rank system, which incorporates these estimate changes, currently ranks Intrusion Inc. at 4 (Sell) [6] Industry Context - The Computer - Networking industry, part of the Computer and Technology sector, holds a Zacks Industry Rank of 50, placing it in the top 21% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Core Viewpoint - Sunrun is experiencing fluctuations in its stock price, with a recent decline of 6.59%, while the company is expected to report significant earnings growth in its upcoming earnings report [1][2]. Company Performance - Sunrun's stock closed at $16.45, down 6.59% from the previous trading session, underperforming the S&P 500, which lost 0.55% [1]. - Over the past month, Sunrun's shares have increased by 7.51%, outperforming the Oils-Energy sector's gain of 1.1% and the S&P 500's gain of 3.64% [1]. Earnings Expectations - The upcoming earnings report is anticipated to show an EPS of $0.03, representing a 108.11% increase year-over-year [2]. - Revenue is expected to reach $606.24 million, indicating a 12.86% increase compared to the same quarter of the previous year [2]. Full Year Projections - For the full year, earnings are projected at $0.71 per share, reflecting a decrease of 46.62% from the previous year, while revenue is expected to be $2.27 billion, showing an increase of 11.2% [3]. Analyst Estimates - Recent changes to analyst estimates for Sunrun are being closely monitored, as upward revisions typically indicate positive sentiment regarding the company's business operations and profit generation capabilities [4]. Zacks Rank and Valuation - Sunrun currently holds a Zacks Rank of 1 (Strong Buy), with the consensus EPS estimate remaining unchanged over the last 30 days [6]. - The company is trading at a Forward P/E ratio of 24.81, which is higher than the industry average Forward P/E of 17.09 [7]. Industry Context - The Solar industry, part of the Oils-Energy sector, has a Zacks Industry Rank of 43, placing it in the top 18% of over 250 industries [7]. - The Zacks Industry Rank measures the strength of industry groups based on the average Zacks Rank of individual stocks, with top-rated industries outperforming lower-rated ones by a factor of 2 to 1 [8].